Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences
01 Giugno 2023 - 2:00PM
Business Wire
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company focused on developing novel therapeutics to treat severe
autoimmune and inflammatory disorders with high unmet medical need,
today announced that it will present at the Jefferies Global
Healthcare Conference and the LD Micro Invitational Conference.
Management will provide an overview of the Company’s
multi-cytokine inhibitor platform focused on EQ101 for the
treatment of alopecia areata and EQ102 for the treatment of celiac
disease, as well as the ongoing development of itolizumab in
partnership with Ono Pharmaceutical, and upcoming milestones.
Management will be available for one-on-one meetings during both
conferences.
Conference:
LD Micro Invitational Conference
Location:
Luxe Hotel, Los Angeles
Date:
Wednesday, June 7
Time:
11:30 am Pacific Time | 2:30 pm Eastern
Time
The presentation at the LD Micro conference will be live-streamed
on the event website at https://ldinv13.sequireevents.com/.
Conference:
Jefferies Global Healthcare Conference
Location:
Marriott Marquis, New York City
Date:
Friday, June 9
Time:
7:30 am Pacific Time | 10:30 am Eastern
Time
Webcast access for the Jefferies conference will be available on
the Events & Presentations page under the Investor Relations
tab on the Company’s website. An archived replay of the Jefferies
conference will be available for 90 days.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel first-in-class immunomodulatory assets targeting
immuno-inflammatory pathways. EQ101: a tri-specific cytokine
inhibitor that selectively targets IL-2, IL-9, and IL-15; currently
under evaluation in a Phase 2 proof-of-concept clinical study of
patients with alopecia areata. EQ102: a bi-specific cytokine
inhibitor that selectively targets IL-15 and IL-21; currently under
evaluation in a Phase 1 first-in-human clinical study to include
healthy volunteers and celiac disease patients. Itolizumab: a
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells;
currently under evaluation in a Phase 3 clinical study of patients
with acute graft-versus-host disease (aGVHD) and a Phase 1b
clinical study of patients with lupus/lupus nephritis. Equillium
acquired rights to itolizumab through an exclusive partnership with
Biocon Limited and has entered a strategic partnership with Ono
Pharmaceutical Co., Ltd. for the development and commercialization
of itolizumab under an option and asset purchase agreement.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of Equillium’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks that contribute
to the uncertain nature of the forward-looking statements include:
Equillium’s ability to execute its plans and strategies; risks
related to performing clinical studies; and whether the results
from clinical studies will validate and support the safety and
efficacy of Equillium’s product candidates. These and other risks
and uncertainties are described more fully under the caption "Risk
Factors" and elsewhere in Equillium's filings and reports, which
may be accessed for free by visiting the Securities and Exchange
Commission’s website at www.sec.gov and on Equillium’s website
under the heading “Investors.” Investors should take such risks
into account and should not rely on forward-looking statements when
making investment decisions. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Equillium undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230601005179/en/
Investor Contact Michael Moore Vice President, Investor
Relations & Corporate Communications 619-302-4431
ir@equilliumbio.com
Grafico Azioni Equillium (NASDAQ:EQ)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Equillium (NASDAQ:EQ)
Storico
Da Mag 2023 a Mag 2024